Werewolf Therapeutics is pioneering conditionally activated macrophage therapies for the treatment of cancer. Their work revolves around PREDATOR, a proprietary platform that designs and engineers macrophages to specifically target and destroy cancer cells. PREDATOR macrophages are activated selectively within the tumor microenvironment, minimizing off-target effects and maximizing therapeutic impact. Werewolf Therapeutics' lead product candidates, WTX-124 and WTX-330, are conditionally activated Interleukin-2 (IL-2) and Interleukin-12 (IL-12) INDUKINE molecules for the treatment of solid tumors. These therapies leverage the inherent tumor-fighting abilities of macrophages to effectively target and eliminate cancer cells while minimizing systemic toxicity.

Werewolf Therapeutics

Founded: 2019
Location: Watertown, MA
Employee range: 11 - 50
Clinical stage: Clin1b
Therapy area: Oncology
Drug types: ONC, IMM
Lead product: WTX-124
Funding: $120M IPO Apr 2021; $72M B Jan 2021; $56M A Nov 2019

Drug notes:

About:

Jobs: